Julius Knowles Sells 2,625 Shares of Keros Therapeutics (NASDAQ:KROS) Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Julius Knowles sold 2,625 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director directly owned 10,958 shares in the company, valued at approximately $117,579.34. This trade represents a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Stock Performance

KROS opened at $10.07 on Wednesday. The firm has a market cap of $199.29 million, a P/E ratio of -3.35 and a beta of 0.94. Keros Therapeutics, Inc. has a 52-week low of $9.79 and a 52-week high of $22.55. The business’s fifty day moving average is $11.30 and its 200-day moving average is $15.05.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The company had revenue of $0.37 million for the quarter, compared to analyst estimates of $1.93 million. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%. On average, research analysts predict that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on KROS. Wells Fargo & Company reduced their target price on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. Wall Street Zen lowered Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings lowered Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Keros Therapeutics has a consensus rating of “Hold” and an average target price of $20.40.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company increased its holdings in Keros Therapeutics by 8.6% in the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after purchasing an additional 988 shares in the last quarter. UBS Group AG increased its holdings in Keros Therapeutics by 1.1% in the third quarter. UBS Group AG now owns 103,864 shares of the company’s stock worth $1,643,000 after purchasing an additional 1,091 shares in the last quarter. Strs Ohio increased its holdings in Keros Therapeutics by 3.9% in the fourth quarter. Strs Ohio now owns 29,300 shares of the company’s stock worth $597,000 after purchasing an additional 1,100 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after purchasing an additional 1,166 shares in the last quarter. Finally, Financial Management Professionals Inc. bought a new stake in Keros Therapeutics in the fourth quarter worth approximately $29,000. 71.56% of the stock is currently owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.